{"title":"Maternal exposure to rubella infection elevates risk of congenital rubella syndrome (CRS).","authors":"Sasikumar Pitchaikani, Pothiaraj Govindan, Harshavardhan Shakila","doi":"10.1016/bs.irn.2025.04.008","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.04.008","url":null,"abstract":"<p><p>The rise in neurodevelopmental disorders linked to maternal viral infections, particularly during the first and second trimesters of pregnancy, is concerning. Rubella, a contagious viral disease, primarily affects children and young adults, presenting as a rash and mild fever. It can also cause symptoms such as a swollen spleen, blueberry muffin skin spots, small head circumference, meningoencephalitis, developmental delays, and jaundice. When contracted in the first trimester, rubella can lead to severe birth defects or fetal death, with the risk declining after 20 weeks. Congenital rubella syndrome (CRS) caused by rubella's teratogenic effects, remains a major public health challenge, with an estimated 100,000 CRS cases annually. Following the approval of the rubella vaccine in 1969, significant strides have been made to reduce CRS and rubella incidences. This chapter provides disease management, prevention strategies, treatment options, and immunological response, focusing on prognosis and insights from current research on rubella and CRS.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"501-526"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of secondary genomes in neurodevelopment and co-evolutionary dynamics.","authors":"Siddharth Singh, Vaishali Saini, Hem Chandra Jha","doi":"10.1016/bs.irn.2025.03.008","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.03.008","url":null,"abstract":"<p><p>This chapter examines how human biology and microbial \"secondary genomes\" have co-evolved to shape neurodevelopment through the gut-brain axis. Microbial communities generate metabolites that cross blood-brain and placental barriers, influencing synaptogenesis, immune responses, and neural circuit formation. Simultaneously, Human Accelerated Regions (HARs) and Endogenous Retroviruses (ERVs) modulate gene expression and immune pathways, determining which microbes thrive in the gut and impacting brain maturation. These factors converge to form a dynamic host-microbe dialogue with significant consequences for neurodevelopmental disorders (NDD), including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and schizophrenia. Building on evolutionary perspectives, the chapter elucidates how genetic and immune mechanisms orchestrate beneficial and pathological host-microbe interactions in early brain development. It then explores therapeutic strategies, such as probiotics, prebiotics, fecal microbiota transplantation, and CRISPR-driven microbial engineering, targeting gut dysbiosis to mitigate or prevent neurodevelopmental dysfunctions. Furthermore, innovative organ-on-chip models reveal mechanistic insights under physiologically relevant conditions, offering a translational bridge between in vitro experiments and clinical applications. As the field continues to evolve, this work underscores the translational potential of manipulating the microbiome to optimize neurological outcomes. It enriches our understanding of the intricate evolutionary interplay between host genomes and the microbial world.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"245-297"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acute disseminated encephalomyelitis - a monophonic illness.","authors":"Nitin Kumar Singh, Varsha Gupta, Siddhartha Kumar Mishra","doi":"10.1016/bs.irn.2025.04.004","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.04.004","url":null,"abstract":"<p><p>Acute Disseminated Encephalomyelitis (ADEM) is an autoimmune condition frequently caused by infections or immunisation activities and is characterised by inflammation and demyelination in the central nervous system (CNS). It primarily affects the brain and spinal cord, typically triggered by an immune response, and most often occurs in children but can also affect adults. The condition usually presents with a rapid onset of neurological symptoms and is considered a monophasic illness, meaning it generally occurs as a single episode. Its attack leads to inflammation and demyelination, impairing nerve signal transmission. Although the exact mechanism is not fully understood, molecular mimicry is thought to play a role, wherein an infection induces an immune response that mistakenly targets CNS antigens resembling the infectious agent. Despite improvements in knowledge and therapies, ADEM is still difficult to diagnose and treat. This chapter covers ADEM's diagnosis, etiology, prognosis, and clinical aspects. It emphasises the interactions between the immune system and the CNS, the individualised treatment plans, and the role of neuroimaging and cerebrospinal fluid investigations in diagnosis. Promising immunomodulatory medications and customised medicine strategies are being developed to enhance patient outcomes, even if corticosteroids are still the primary therapy.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"473-499"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Microbiome-based dietary supplements for better development and healthy brain.","authors":"Riddhi Upadhyay, Sugumar Mani, Murugan Sevanan","doi":"10.1016/bs.irn.2025.03.009","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.03.009","url":null,"abstract":"<p><p>Microbiome-based dietary supplements have gained attention for their role in enhancing brain development and cognitive health. The gut microbiome influences neurological functions through the gut-brain axis, impacting neurotransmitter production, immune regulation, and metabolic pathways. Dysbiosis is linked to neurological disorders such as Alzheimer's, Parkinson's, and autism spectrum disorders. This chapter explores dietary interventions targeting the microbiome, emphasising probiotics, prebiotics, and postbiotics. Additionally, AI and machine learning are transforming microbiome research by enabling personalised supplementation strategies tailored to individual gut profiles. Ethical challenges, including data privacy and algorithmic bias, are also discussed. Advances in big data analytics and predictive modelling are paving the way for precision-targeted interventions to optimise brain health. While microbiome-based therapies hold great promise, further clinical validation and regulatory frameworks are needed to ensure their efficacy and accessibility. This chapter highlights the future potential of microbiome-targeted strategies in neuroprotection and cognitive well-being.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"329-368"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Retrospective link of altered mental status and cryptococcal meningitis.","authors":"Punithkumar Naraganahalli Krishnaraj, Chandavi Venkatesh, Dhanu Anneyplar Shivakumar, Nagalambika Prasad, Guru Kumar Dugganaboyana, Kumar Jajur Ramanna","doi":"10.1016/bs.irn.2025.04.003","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.04.003","url":null,"abstract":"<p><p>Cryptococcal meningitis (CM) is a severe central nervous system infection primarily affecting immunocompromised patients, significantly contributing to global morbidity and mortality. This chapter explores the link between altered mental status (AMS) and CM, focusing on pathophysiological mechanisms and clinical correlations. Cryptococcus neoformans invades the central nervous system, evading immune defenses and causing increased intracranial pressure, inflammation, and neuronal damage. AMS, a frequent early symptom in CM, signals neurological involvement and disease severity, ranging from subtle cognitive issues to severe deficits. Retrospective studies highlight AMS as a prognostic marker, often associated with worse outcomes. Diagnostic challenges are discussed, emphasizing early recognition for timely intervention. Advances in artificial intelligence and machine learning are proposed to enhance diagnostic accuracy, prognosis, and management of CM. The chapter also covers antifungal therapies and supportive interventions to mitigate AMS-related complications. Future research directions include AI-driven diagnostics and novel treatments to improve outcomes in CM and its neurological manifestations.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"435-472"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intestinal dysbiosis leads to the reduction in neurochemical production in Parkinson's disease (PD).","authors":"Rahul Kumar, Rahul Kumar","doi":"10.1016/bs.irn.2025.03.004","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.03.004","url":null,"abstract":"<p><p>Parkinson's Disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, with emerging research suggesting a critical link between intestinal dysbiosis and PD progression. This review explores the pathophysiological mechanisms underlying PD, such as alpha-synuclein aggregation, mitochondrial dysfunction, neuroinflammation, and oxidative stress, while focusing on the impact of gut dysbiosis on intestinal barrier function and its role in reduced neurochemical production. The clinical features of PD, including dopamine, serotonin, and GABA deficiencies, are examined, with a focus on how dysbiosis contributes to neurotransmitter depletion. Current treatments of PD, such as levodopa and dopamine agonists, are discussed alongside gut health therapies such as probiotics, prebiotics, and Fecal Microbiota Transplantation (FMT). Future therapeutic directions, including synbiotics, engineered microbes, phage therapy, and the integration of machine learning (ML) and artificial intelligence (AI), are explored. The chapter also considers preventive strategies, such as lifestyle adjustments and early gut health monitoring using modern diagnostic tools and biosensors. Furthermore, a strong need for continued research into the gut-brain axis (GBA) to develop more effective, gut-targeted therapies for managing PD is discussed.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"25-56"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Viral agents in neuromuscular pathology.","authors":"Abhay Kumar Singh, Yemgadda Goutham Sudhan, Ramakrisha Ramakrishna, Siva Sundara Kumar Durairajan","doi":"10.1016/bs.irn.2025.04.007","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.04.007","url":null,"abstract":"<p><p>In recent years, viral infections have been increasingly identified as major players in neuromuscular pathologies. This chapter presents an overview of the evidence and future directions for virus-induced neuromuscular disorders. Information is integrated on the global burden of these diseases related to epidemiology, clinical features, diagnosis, treatment, and preventive strategies was integrated. Responsible viruses include enteroviruses, flaviviruses, herpesviruses, and emerging pathogens such as SARS-CoV-2. It represents a broad spectrum of neuromuscular disorders, including Guillain-Barré syndrome, viral myositis, and critical illness neuropathy/myopathy. The book chapter discusses different diagnostic approaches, therapy strategies, and rehabilitation methods, in addition to early intervention and preventive measures. This has led to new insights into novel therapies, unmet research needs, and future perspectives on viral neuromuscular disorders. This chapter demonstrates that supporting both clinical care and patient management with clinical research entails a profound understanding of the difficult interactions between the viruses concerned and the neuromuscular system.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"397-434"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bacterial meningitis is a significant catalyst for neuroinflammation.","authors":"Sudharsan Parthasarathy, Siva Vijayakumar Tharumasivam, Ashajyothi Chavaan, Bupesh Giridharan, Archana Sundaram","doi":"10.1016/bs.irn.2025.03.010","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.03.010","url":null,"abstract":"<p><p>Bacterial meningitis is a severe infection that can lead to neuroinflammation, posing risks to the central nervous system (CNS). This inflammation, if uncontrolled, can cause long-term neurological damage, cognitive decline, and neuron injury. Management strategies include telemedicine and remote monitoring, enabling continuous observation and timely adjustments in treatment. Early detection through biosensor technology is vital, offering healthcare providers insights for proactive intervention before critical issues arise. Nutritional support, particularly hydration, is also emphasized to strengthen immune response and potentially delay disease progression. The chapter highlights the transformative potential of Artificial Intelligence (AI) and machine learning in disease management, from prognostic assessments to creating personalized treatment plans. By integrating AI-driven insights with advanced monitoring and preventive approaches, healthcare providers can mitigate the impact of bacterial meningitis, enhancing patient outcomes and recovery potential.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"369-396"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Disruption in the human microbiome causing behavioural changes in bipolar disorder.","authors":"Subramani Srinivasan","doi":"10.1016/bs.irn.2025.04.001","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.04.001","url":null,"abstract":"<p><p>This chapter explores the intriguing and complex relationship between the human microbiome and Bipolar Disorder (BD). The microbiome, notably the gut microbiota, has been increasingly recognised as a key performer in brain health and disease. This is due to its role in the gut-brain axis, a bidirectional communication between the gastrointestinal tract and the central nervous system. Disruptions in the gut microbiota due to factors such as diet, and stress, may influence this axis and potentially trigger or exacerbate psychiatric conditions. Hence, we investigate into the present interpretation of the microbiome's role in mental health, concentrating on its impact on mood regulation and cognitive function. Consequently, we also explore the possible mechanisms through which microbiome disruption may pay to the behavioural changes observed in BD. Further exploration understand the complex interplay between the microbiome and BD and translate these findings into effective therapeutic plans.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"157-187"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sadari Manusha, N Varsha, R Varshini, Yuvaraj Sivamani, Kiran Sree Pokkuluri, Sumitha Elayaperumal
{"title":"Altered microbiome influence on the enteric neuromuscular system in amyotrophic lateral sclerosis (ALS).","authors":"Sadari Manusha, N Varsha, R Varshini, Yuvaraj Sivamani, Kiran Sree Pokkuluri, Sumitha Elayaperumal","doi":"10.1016/bs.irn.2025.04.006","DOIUrl":"https://doi.org/10.1016/bs.irn.2025.04.006","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a neurological disease marked by the degeneration of motor neurons, leading to muscle weakness and paralysis. While the cause of ALS is uncertain, research indicates that changes in the gut microbiome may influence the disease's progression. This chapter explores how alterations in gut microbiota affect the enteric neuromuscular system (ENS) in ALS. In ALS patients, disrupted gut microbiota are linked to the brain-gut axis, impacting both gastrointestinal function and neuronal health. Studies show that microbial changes are associated with inflammation, immune instability, and neurodegeneration, which exacerbate the disease. Gastrointestinal issues like constipation and dysphagia in ALS are tied to ENS dysregulation. Understanding the connections between the gut microbiome, ENS, and central nervous system (CNS) may lead to novel therapies targeting neurodegeneration and microbial dysbiosis in ALS.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"180 ","pages":"95-123"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}